Abstract
Sivelestat sodium hydrate (sivelestat) is a selective inhibitor of polymorphonuclear leukocyte elastase (PMN-E). We administered sivelestat to patients with septic acute lung injury (ALI) to examine its usefulness. The primary endpoints in the study were the duration of artificial ventilation and pulmonary oxygenation ability, and the secondary endpoints were mortality and the concentrations of PMN-E, SP-D, TNF-alpha and IL-8 in blood. In the sivelestat group, the duration of artificial ventilation, pulmonary oxygenation ability, and the blood PMN-E, SP-D, TNF-alpha and IL-8 concentrations decreased significantly. Administration of sivelestat was found to reduce alveolar dysfunction and improve respiratory function, and it was suggested that early administration might be useful.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Aged
-
Glycine / administration & dosage
-
Glycine / analogs & derivatives*
-
Glycine / therapeutic use
-
Humans
-
Interleukin-8 / blood
-
Leukocyte Elastase / antagonists & inhibitors
-
Leukocyte Elastase / blood
-
Leukocytes / drug effects*
-
Middle Aged
-
Oxygen / blood
-
Pulmonary Circulation / drug effects*
-
Pulmonary Surfactant-Associated Protein D / blood
-
Respiration, Artificial / statistics & numerical data
-
Serine Proteinase Inhibitors / administration & dosage
-
Serine Proteinase Inhibitors / therapeutic use*
-
Sulfonamides / administration & dosage
-
Sulfonamides / therapeutic use*
-
Survival Analysis
-
Systemic Inflammatory Response Syndrome / drug therapy*
-
Systemic Inflammatory Response Syndrome / immunology
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / blood
Substances
-
Interleukin-8
-
Pulmonary Surfactant-Associated Protein D
-
Serine Proteinase Inhibitors
-
Sulfonamides
-
Tumor Necrosis Factor-alpha
-
sivelestat
-
Leukocyte Elastase
-
Oxygen
-
Glycine